-
Je něco špatně v tomto záznamu ?
Cystatin C measurement leads to lower metformin dosage in elderly type 2 diabetic patients
T. Šálek, A. Adamíková,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, pozorovací studie
PubMed
30218617
DOI
10.1111/bcpt.13132
Knihovny.cz E-zdroje
- MeSH
- chronická renální insuficience krev patofyziologie MeSH
- cystatin C krev MeSH
- diabetes mellitus 2. typu krev farmakoterapie patofyziologie MeSH
- hodnoty glomerulární filtrace fyziologie MeSH
- hypoglykemika aplikace a dávkování MeSH
- kreatinin krev MeSH
- lidé MeSH
- metformin aplikace a dávkování MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- věkové faktory MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
The aim of this study was to provide evidence for the hypothesis that estimated glomerular filtration rate from serum Cystatin C (eGFRcys) is better to be determined for all elderly type 2 diabetes mellitus (T2DM) patients based on eGFRcys upward and downward reclassification rate for hypothetical metformin dose reduction by eGFRcys at the GFR decision point of 45 mL/min/1.73 m2 . A total of 265 consecutive T2DM elderly patients (age range 65-91 years) from outpatient diabetic clinic were included in the study. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines for metformin dosing were strictly followed. Estimated glomerular filtration rate from serum creatinine (eGFRcrea) led to results of metformin eligibility. Each of the results of eGFRcrea-based eligibility was further compared to eGFRcys-based eligibility. Creatinine was measured by enzymatic method standardized against international reference material SRM 967. Cystatin C was determined by method traceable to DA ERM 471 international standard. eGFRcrea and eGFRcys were calculated according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. A downward reclassification rate was higher than upward reclassification rate (31 vs 3, respectively; P < 0.0001). The median (IQR) eGFRcrea was higher than eGFRcys (73 (58-85) vs 63 (50-75) mL/min/1.73 m2 , respectively; P < 0.0001). eGFRcys reclassified significant proportion of patients with T2DM from metformin eligible CKD stages to less or non-eligible stages. The downward reclassification was more frequent in patients older than 80 years (P < 0.01). Cystatin C-based eGFR selects more complicated patients, where lower doses of metformin are possibly advisable. We recommend calculating both eGFRcrea and eGFRcys for metformin dosing in elderly patients with T2DM.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035015
- 003
- CZ-PrNML
- 005
- 20200221132303.0
- 007
- ta
- 008
- 191007s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bcpt.13132 $2 doi
- 035 __
- $a (PubMed)30218617
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Šálek, Tomáš, $u Department of Clinical Biochemistry and Pharmacology, Tomas Bata Hospital in Zlín a. s., Zlín, Czech Republic. Department of Biomedical sciences, Medical Faculty, University of Ostrava, Ostrava, Zábřeh, Czech Republic. $d 1974- $7 xx0174625
- 245 10
- $a Cystatin C measurement leads to lower metformin dosage in elderly type 2 diabetic patients / $c T. Šálek, A. Adamíková,
- 520 9_
- $a The aim of this study was to provide evidence for the hypothesis that estimated glomerular filtration rate from serum Cystatin C (eGFRcys) is better to be determined for all elderly type 2 diabetes mellitus (T2DM) patients based on eGFRcys upward and downward reclassification rate for hypothetical metformin dose reduction by eGFRcys at the GFR decision point of 45 mL/min/1.73 m2 . A total of 265 consecutive T2DM elderly patients (age range 65-91 years) from outpatient diabetic clinic were included in the study. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines for metformin dosing were strictly followed. Estimated glomerular filtration rate from serum creatinine (eGFRcrea) led to results of metformin eligibility. Each of the results of eGFRcrea-based eligibility was further compared to eGFRcys-based eligibility. Creatinine was measured by enzymatic method standardized against international reference material SRM 967. Cystatin C was determined by method traceable to DA ERM 471 international standard. eGFRcrea and eGFRcys were calculated according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. A downward reclassification rate was higher than upward reclassification rate (31 vs 3, respectively; P < 0.0001). The median (IQR) eGFRcrea was higher than eGFRcys (73 (58-85) vs 63 (50-75) mL/min/1.73 m2 , respectively; P < 0.0001). eGFRcys reclassified significant proportion of patients with T2DM from metformin eligible CKD stages to less or non-eligible stages. The downward reclassification was more frequent in patients older than 80 years (P < 0.01). Cystatin C-based eGFR selects more complicated patients, where lower doses of metformin are possibly advisable. We recommend calculating both eGFRcrea and eGFRcys for metformin dosing in elderly patients with T2DM.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kreatinin $x krev $7 D003404
- 650 _2
- $a cystatin C $x krev $7 D055316
- 650 _2
- $a diabetes mellitus 2. typu $x krev $x farmakoterapie $x patofyziologie $7 D003924
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a hodnoty glomerulární filtrace $x fyziologie $7 D005919
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $x aplikace a dávkování $7 D007004
- 650 _2
- $a metformin $x aplikace a dávkování $7 D008687
- 650 _2
- $a chronická renální insuficience $x krev $x patofyziologie $7 D051436
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Adamíková, Alena $u Diabetes Center, Tomas Bata Hospital in Zlín, a. s., Zlín, Czech Republic.
- 773 0_
- $w MED00007578 $t Basic & clinical pharmacology & toxicology $x 1742-7843 $g Roč. 124, č. 3 (2019), s. 298-302
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30218617 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20200221132708 $b ABA008
- 999 __
- $a ok $b bmc $g 1451675 $s 1073565
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 124 $c 3 $d 298-302 $e 20181017 $i 1742-7843 $m Basic & clinical pharmacology & toxicology $n Basic Clin Pharmacol Toxicol $x MED00007578
- LZP __
- $a Pubmed-20191007